Tirzepatide for obesity treatment and diabetes prevention
New England Journal of Medicine
2025
Study summary
Long-term SURMOUNT-1 data evaluated tirzepatide for obesity with prediabetes.
Peptides studied
Goals studied
Stack studied
Advanced Metabolic Stack
Key findings
Tirzepatide reduced weight and delayed progression to type 2 diabetes over three years.
Study details
Study type
randomized clinical trial
Journal
New England Journal of Medicine
DOI / PubMed
10.1056/NEJMoa2409773
Year
2025
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.
